Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation

被引:0
作者
G. Hutter
M. Scheubner
G. Ott
Y. Zimmermann
K. Hübler
S. Roth
S. Stilgenbauer
J. Kalla
H. Stöcklein
W. Hiddemann
M. Dreyling
机构
[1] University Hospital Grosshadern/LMU,Department of Medicine III
[2] CCG Leukemia,Institute of Pathology
[3] Helmholtz Zentrum München,Department of Internal Medicine III
[4] German Research Center for Environmental Health,undefined
[5] University of Wuerzburg,undefined
[6] University of Ulm,undefined
来源
Annals of Hematology | 2009年 / 88卷
关键词
MCL; LOH analysis; Cell proliferation; 17p13;
D O I
暂无
中图分类号
学科分类号
摘要
Mantle cell lymphoma (MCL) is a distinct subentity of non-Hodgkin lymphoma, characterized by the chromosomal translocation t(11;14)(q13;q32) leading to an overexpression of cyclin D1 in virtually all cases. However, additional cytogenetic aberrations are apparent in the vast majority of MCL. Applying LOH analysis in 52 MCL patient samples, we confirmed frequent alterations in 9p21 (28.6%) and p53 (28.9%) but also detected allelic losses in 1p21, 9q21, 13q13-14, 13q31-32, 17p13.1, and 17p13.3 in 28–45% of cases and allelic gains in 3q27-28 and 19p13.3 in 14–22% of cases. In addition, losses in the 2p23 and 7q22-35 genomic regions not previously described to be altered in MCL were identified in up to 20% of cases. Applying multivariate analysis, a cluster of genomic aberrations including 1p21, 3q27, 7q22-36, 6p24, 9p21, 9q31, and 16p12 alterations was identified which was closely associated to cell proliferation as determined by Ki67 immunostaining. This proliferation-dependent network of oncogenic alterations complements the previously identified proliferation expression signature described by RNA expression profiling in MCL.
引用
收藏
页码:821 / 828
页数:7
相关论文
共 50 条
  • [21] Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
    Samad, Nousheen
    Younes, Anas
    ONCOTARGETS AND THERAPY, 2010, 3 : 167 - 178
  • [22] Survival Prediction Models (AIIMS Mantle Cell Lymphoma Overall Survival [AMOS] Score and AIIMS Mantle Cell Lymphoma Event-Free Survival [AMES] Score) for Patients With Mantle Cell Lymphoma From Indian Population
    Datta, Soumyadeep
    Gogia, Ajay
    Sharma, Atul
    Wig, Naveet
    Sagiraju, Hari Krishna Raju
    Mallick, Saumyaranjan
    Gupta, Ritu
    Pandey, Shivam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S513 - S513
  • [23] Autoimmune Cytopenia and Mantle Cell Lymphoma: A Case Report
    Maataoui-Belabbes, Hajar
    Benmoussa, Amine
    Cherkaoui, Siham
    Lamchahab, Mouna
    Qachouh, Meryem
    Rachid, Mohamed
    Madani, Abdellah
    Khoubila, Nisrine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S460 - S461
  • [24] Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network
    Cheah, C. Y.
    George, A.
    Gine, E.
    Chiappella, A.
    Kluin-Nelemans, H. C.
    Jurczak, W.
    Krawczyk, K.
    Mocikova, H.
    Klener, P.
    Salek, D.
    Walewski, J.
    Szymczyk, M.
    Smolej, L.
    Auer, R. L.
    Ritchie, D. S.
    Arcaini, L.
    Williams, M. E.
    Dreyling, M.
    Seymour, J. F.
    ANNALS OF ONCOLOGY, 2013, 24 (08) : 2119 - 2123
  • [25] Efficacy of Orelabrutinib in Mantle Cell Lymphoma: A Systematic Review
    Anjum, Zauraiz
    Zarrar, Raza
    Anwar, Junaid
    Mandal, Shobha
    Ahmed, Mirza Fawad
    Arslan, Hafiz Muhammad
    Ahmed, Zahoor
    Nazar, Tazeen
    Tariq, Mahrukh
    Khan, Muzamil
    Zafar, Maha
    Noor, Ahdia
    Anwer, Faiz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S516 - S516
  • [26] A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
    Yazbeck, Victor
    Shafer, Danielle
    Perkins, Edward B.
    Coppola, Domenico
    Sokol, Lubomir
    Richards, Kristy L.
    Shea, Thomas
    Ruan, Jia
    Parekh, Samir
    Strair, Roger
    Flowers, Christopher
    Morgan, David
    Kmieciak, Maciej
    Bose, Prithviraj
    Kimball, Amy
    Badros, Ashraf Z.
    Baz, Rachid
    Lin, Hui-Yi
    Zhao, Xiuhua
    Reich, Richard R.
    Tombes, Mary Beth
    Shrader, Ellen
    Sankala, Heidi
    Roberts, John D.
    Sullivan, Daniel
    Grant, Steven
    Holkova, Beata
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09) : 569 - +
  • [27] Patterns and Outcome of Relapse After Autologous Stem Cell Transplantation for Mantle Cell Lymphoma
    Dietrich, Sascha
    Tielesch, Blanca
    Rieger, Michael
    Nickelsen, Maike
    Pott, Christiane
    Witzens-Harig, Mathias
    Kneba, Michael
    Schmitz, Norbert
    Ho, Antony D.
    Dreger, Peter
    CANCER, 2011, 117 (09) : 1901 - 1910
  • [28] Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma
    Yamasaki, Satoshi
    Chihara, Dai
    Kim, Sung-Won
    Izutsu, Koji
    Iwato, Kouji
    Fukuda, Takahiro
    Uchida, Naoyuki
    Amano, Itsuto
    Nakazawa, Hideyuki
    Kuroda, Junya
    Hashimoto, Hisako
    Ichinohe, Tatsuo
    Kanda, Yoshinobu
    Atsuta, Yoshiko
    Suzumiya, Junji
    Suzuki, Ritsuro
    ANNALS OF HEMATOLOGY, 2018, 97 (08) : 1445 - 1452
  • [29] Alterations of Cell Proliferation and Apoptosis in the Hypoplastic Reeler Cerebellum
    Cocito, Carolina
    Merighi, Adalberto
    Giacobini, Mario
    Lossi, Laura
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2016, 10
  • [30] Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma
    Cohen, BJ
    Moskowitz, C
    Straus, D
    Noy, A
    Hedrick, E
    Zelenetz, A
    LEUKEMIA & LYMPHOMA, 2001, 42 (05) : 1015 - +